Maha Katabi

Maha Katabi, PhD, CFA is a General Partner of Sofinnova Investments. She is an experienced investor with over two decades in managing public and private biotech companies through bull and bear markets. She is currently a board member of ARTBIO, Marea, Quanta, Star, and Vera (VERA). Most recently Maha was a board member of Aiolos (acquired by GSK) and RayzeBio (RYZB: acquired by BMS), in addition to Amplyx (acquired by Pfizer), Gyroscope (acquired by Novartis) and Northsea.

Prior to joining Sofinnova, Maha was a Partner at Sectoral Asset Management. She started her career in venture as a principal investor with associate and principal roles at T2C2/Bio and Ventures West. Maha serves as an advisor to amplifyHERscience, a Yale Ventures initiative.

She received a Ph.D. in Pharmacology and a B.Sc. in Biology at McGill University and is a CFA charterholder.

Please note that speakers provide their own biographies and headshots. Biographies represent the role of the person at the time of their engagement and are not independently verified by the Milken Institute.